Aims: Ghrelin is implicated in the control of energy balance and glucose homeostasis. The ghrelin receptor exhibits ligand-independent constitutive activity, which can be pharmacologically exploited to induce inverse ghrelin actions. Because ghrelin receptor inverse agonists (GHSR-IA) might be effective for the treatment of obesity-related metabolic disease, we tested 2 novel synthetic compounds GHSR-IA1 and GHSR-IA2.
| INTRODUCTION
Ghrelin controls energy homeostasis and acts via the growth hormone secretagogue receptor (GHS-R). 1, 2 Ghrelin is released from the stomach during fasting and before meals, while feeding or glucose intake reduce its circulating levels. 3, 4 The GHS-R is expressed in neurons of the hypothalamic arcuate nucleus that contain the orexigenic neuropeptide Y. 5 Ghrelin stimulates food intake (FI) in rodents and humans, and promotes adiposity. 3, 6 Ghrelin inhibits insulin release and leads to insulin resistance. [7] [8] [9] Accordingly, ghrelin-deficient mice show increased insulin secretion and are protected against high-fat diet-induced glucose intolerance. 7 Moreover, insulin sensitivity is improved in high-fat diet-fed GHS-R knockout mice. 10 In the liver, ghrelin counteracts insulin signalling by promoting the expression of the gluconeogenic enzyme phosphoenolpyruvat-carboxykinase. 11 Further, ghrelin increases lipogenic enzyme activity and inhibits lipid oxidation in white fat. 12, 13 The ghrelin signalling pathway is a potential pharmacological target for the treatment of obesity-related metabolic disorders.
Most prior approaches were based on a blockade of ghrelin signalling by inhibition of ghrelin acylation or secretion, by inactivation of ghrelin via vaccination or ghrelin binding, or by blockade of the GHS-R by receptor antagonists. 14 However, these therapeutic strategies had limited effects because ghrelin levels are decreased rather than increased in most obese compared with lean subjects. 15 The GHS-R exhibits strong constitutive activity of about 50% of maximum signalling activity. 16 Hence, GHS-R signalling is in part independent of ghrelin action and can therefore only be partially inhibited by pharmacological approaches blocking ghrelin binding to the GHS-R. However, pharmacological inhibition of the constitutive activity of the GHS-R by ghrelin receptor inverse agonists (GHSR-IA) allows suppression of GHS-R signalling below the level achieved by inactivation or antagonism of ghrelin. The first identified GHSR-IA compound was an artificial substance P analogue. 16 In our current studies, we explored the effects of two novel ghrelin receptor inverse agonists (GHSR-IA1 and GHSR-IA2) on energy homeostasis, and glucose and lipid metabolism using rodent models for obesity-related metabolic disorders. Both compounds belong to the same class of artificial small molecule compounds (see scaffold in Figure S1 ). Among a variety of other molecules that were developed, these 2 compounds exhibited the most promising characteristics with respect to pharmacokinetic parameters and biological activity. GHSR-IA2 is the more advanced compound exhibiting better characteristics and predicted effectiveness. For these reasons, we included both test compounds in our studies. Because the two drugs are closely related in terms of structure, pharmacology and biological activity, we did not conduct all experiments with both substances to avoid experimental redundancy. In experiments 1 and 2 (functional receptor studies), both compounds were tested for the demonstration of inverse agonist properties. (TSE Systems, Bad Homburg, Germany), as described previously. 21 Mice were treated daily with GHSR-IA1 (30 mg/kg s.c.) or vehicle.
Vehicle-treated mice were pair-fed, i.e. they received the same amount of food that GHSR-IA1-treated animals had eaten the previous day. Injections were always given just before dark onset for 6 days. Injections were performed 1 hour before dark onset for 10 days.
OGTTs were performed after 5 and 10 days of treatment. Animals were killed by exsanguination under isoflurane anaesthesia 1 day after the final OGTT. Blood was collected from the right ventricle, and pancreas and liver samples were obtained.
| Statistics
Data are expressed as means AE SE and analysed using Student's ttest (paired or unpaired), 1-way ANOVA, or Kruskal-Wallis test as appropriate. Tukey's post hoc tests (ANOVA) or Dunn's multiple comparisons test were used to determine differences between groups. A P-value of <.05 was considered significant. and GHSR-IA2 (FLIPR assay) were 38 and 1.2 nM, respectively (see Figures S1, S2 and S4 for additional compound characteristics).
| Experiment 3: GHSR-IA reduced activity of ghrelin-excited neurons
All eight tested neurons were excited by ghrelin, while GHSR-IA1 ( 3.5 | Experiment 11: effect of GHSR-IA1 on energy expenditure and respiratory exchange rate (RER)
GHSR-IA1 treatment increased energy expenditure compared with pair-fed mice ( Figure 3 ). The effects of GHSR-IA1 treatment on dark and light phase energy expenditure were also evident when data were corrected for BW, i.e. energy expenditure was only significantly increased during the light phase. There was no effect of repeated GHSR-IA1 treatment on RER in chow-fed mice. Means with different letters or symbols are significantly different from each other; *P < .05; **P < .01; ***P < .001 hyperplasia to islet fibrosis was attenuated by GHSR-IA1 reflected by a reduced ratio of fibrotic to hyperplastic islets ( Figure 4K-M) . Terminal insulin values were not significantly different between the groups (see File S1).
| Experiments 13 and 14: GHSR-IA treatment reduced FI, BW and improved glucose tolerance in DIO mice
Daily treatment with GHSR-IA1 and GHSR-IA2 (30 mg/kg s.c.) significantly reduced daily FI compared with controls ( Figure 5A and B).
BW gain was significantly reduced compared with ad libitum-fed controls ( Figure 5C ). GHSR-IA2 reduced BW compared with ad libitumfed controls at the end of the 10-day treatment period ( Figure 5D ).
Although pair-fed mice had a higher BW than the GHSR-IA2-treated mice at that time point, the difference was not statistically significant.
However, there were clear differences in BW change between the three treatment groups ( Figure 5E ). GHSR-IA2-treated mice lost 14.4% of their BW, while weight loss in pair-fed mice vs ad libitumfed controls was significantly smaller (7.7%) than in the GHSR-IA2
group. Although GHSR-IA2-treated mice had the lowest total and subcutaneous fat mass, the differences did not reach statistical significance ( Figure 5F and G). Interestingly and similar to the ZDF rats, GHSR-IA2-treated mice had significantly less visceral fat mass than ad libitum-fed controls, while lean body mass was almost identical in all groups ( Figure 5H and I). were not due to aversion because neither GHSR-IA1 nor GHSR-IA2 caused a CTA response.
GHSR-IA1 increased energy expenditure, which is consistent with a decrease of energy expenditure by ghrelin via a suppression sympathetic innervation of brown adipose tissue 26, 27 and by inhibiting uncoupling protein 1 (UCP-1) expression. 13 We cannot exclude that differences in physical activity might have influenced energy expenditure. Although cumulative dark phase energy expenditure was not different between the groups, there was a prominent increase in energy expenditure of the GHRS-IA1 group in the second half of the dark phase, which might be activity-related. While RER was not affected by GHSR-IA1, the effect of ghrelin or GHS-R signalling on fat utilization appears to be diet-dependent because a reduction in RER has been observed in GHS-R-deficient mice maintained under a high-fat diet. 28 We did not test whether GHSR-IA1 treatment reduces RER under high-fat diet feeding conditions, which seems plausible based on these findings.
Repeated GHSR-IA1 treatment reduced FI in ZDF rats. Interestingly, visceral adiposity was decreased by GHSR-IA1 treatment, which is therapeutically more relevant than a reduction of subcutaneous adiposity given the importance of visceral fat depots for metabolic dysregulation. 29 The selective loss of visceral adipose tissue might be due to higher lipolytic or lower anti-lipolytic responsiveness, and reduced lipogenic activity compared with subcutaneous fat, either directly induced by GHSR-IA1 or indirectly via other mechanisms. Blood triglycerides and free fatty acids tended to be reduced in GHSR-IA1-treated ZDF rats. The decreased visceral adiposity and possibly subsequent changes in liver lipid metabolism might have contributed to this tendency. In fact, hypertriglyceridaemia has been demonstrated to be the only independent correlate of visceral adiposity among several biometric and metabolic parameters in obese humans. 30 The most striking effect of GHSR-IA1 in ZDF rats was the improvement in OGT. This effect was unrelated to BW loss, because
at least in this model GHSR-IA1 did not significantly affect total BW, fat or lean mass. The reduction in visceral adiposity and the metabolic by Kruskal-Wallis test followed by Dunn's multiple comparisons test, respectively. N = 9 to 10 for all data, *P < .05; **P < .01, ***P < .001; GHSR-IA1 or GHSR-IA2 vs vehicle: a P < .05, aa P < .01, aaa P < .001; accordingly pair-fed/vehicle vs vehicle: b; GHSR-IA1 or GHSR-IA2 vs pair-fed/vehicle: c consequences discussed above probably do not solely account for the improved glucose tolerance. Acute ghrelin treatment induces peripheral insulin resistance in humans. 31 Therefore, an improvement of insulin sensitivity by GHSR-IA1 possibly contributed to the restoration of glucose tolerance in ZDF rats. In addition, ghrelin signalling exerts a diabetogenic effect in rodents 7, 32 and humans 8, 9 by inhibiting insulin secretion. It was beyond the scope of our studies to dissociate effects of GHSR-IA1 treatment on insulin sensitivity and insulin secretion, respectively.
The development of pancreatic islet fibrosis is a histopathological hallmark of islet dysfunction. As a compensatory response to hyperglycaemia, beta-cells start to proliferate leading to beta-cells hypertrophy and hyperplasia 33, 34 Pancreatic stellate cells are also activated by hyperglycaemia and hyperinsulinaemia in an additive manner, 35 and secrete extracellular matrix proteins contributing to fibrosis.
Interestingly, ZDF rats show a more severe degree and earlier onset of pathological islet characteristics (including fibrosis) than obese non-diabetic Zucker fatty rats. 36 The amelioration of glucose homeostasis by GHSR-IA1 is a plausible mechanism that might have counteracted the development of islet fibrosis from islet hyperplasia in our studies. The treatment-dependent reduction of fibrotic vs hyperplastic islets without an increase of normal islets indicates that the treatment probably was not able to reverse hyperplasia that preexisted before the start of treatment. Whether earlier initiation and longer treatment duration might also prevent the development of islet hyperplasia remains to be demonstrated.
In line with our observations in DIO mice, GHS-R-null mice kept on a high-fat diet show reduced FI, supporting the crucial role of constitutive GHS-R activity in the control of feeding behaviour. 28 GHSR-IA2-treated DIO mice showed absolute loss of BW and visceral fat GSHR-IA1 treatment strongly reduced liver steatosis in DIO mice. The possible therapeutic value of this treatment effect is substantial because hepatic steatosis (HS) is part of a spectrum of pathological changes that are categorized as non-alcoholic fatty liver disease (NAFLD). 40 Obesity and type 2 diabetes mellitus (T2DM) are major risk factors for NAFLD-related liver transplantation. 41 A shift of lipids from adipose tissue into ectopic sites, particularly the liver, promotes the development of NAFLD. Insulin resistance plays a crucial role in this process. 42 Chronic ghrelin treatment induces liver steatosis in rats and mice maintained on standard chow and high-fat diet, 12 while GHS-R-deficient mice are protected against high-fat diet-induced liver steatosis. The effect of GHS-R signalling on HS appears to depend on an mTOR-PPAR-γ signalling pathway promoting lipogenesis in hepatocytes. 43 Hence, in addition to improved glucose homeostasis and insulin sensitivity, the protective effect of GHSR-IA1 against liver steatosis could involve a direct inhibition of hepatic lipogenesis.
Finally, the beneficial effects of GHSR-IA treatment on BW, visceral adiposity and glucose homeostasis were paralleled by improved blood lipid profiles. GHSR-IA2 was more effective because it also significantly reduced the blood triglyceride level. In the GHSR-IA2 studies blood lipid profiles of pair-fed mice were similar to the treatment group indicating an indirect action probably via the reduction of FI. Although the effect of GHSR-IA2 treatment on HDL levels did not reach statistical significance in our studies, HDL values might be positively influenced under longer treatment durations ( Figure S7 ).
In summary, we confirmed inverse ghrelin receptor agonist responses on the functional single cell and in vivo level. While both tested compounds showed beneficial effects on energy balance and glucose homeostasis, GHSR-IA2 appeared to be more effective, which is in line with pharmacological profiles. We demonstrated in two rodent models that GHSR-IA are promising therapeutic compounds for the treatment of obesity-related metabolic disorders such as T2DM and comorbidities contributing to the metabolic syndrome.
